Ocuphire Pharma Inc. Stock
Ocuphire Pharma Inc. Stock
There is an upward development for Ocuphire Pharma Inc. compared to yesterday, with an increase of €0.080 (2.260%).
Our community identified positive and negative aspects for Ocuphire Pharma Inc. stock for the coming years. 2 users see the criterium "Worthwhile Investment for the next years" as a plus for the Ocuphire Pharma Inc. stock. On the other hand our users think that "Innovation" could be a problem in the future.
Pros and Cons of Ocuphire Pharma Inc. in the next few years
Pros
?
M***** P*******
?
C******** o* t** e**********
?
S********** s********
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Ocuphire Pharma Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Ocuphire Pharma Inc. | 2.260% | 11.538% | 30.827% | 252.584% | 106.897% | -5.563% | -2.247% |
| Actinium Pharmaceuticals Inc. | -0.110% | 4.276% | 18.727% | -36.217% | -21.210% | -82.865% | -81.712% |
| NanoViricides Inc. | 0.000% | -5.983% | -21.986% | -4.348% | 18.280% | -5.172% | -63.062% |
| AnaptysBio Inc | -4.000% | 0.516% | 9.317% | 183.081% | 13.233% | 172.011% | 136.359% |
Comments
Ocuphire Pharma, Inc. (NASDAQ: OCUP) had its price target lowered by analysts at HC Wainwright from $20.00 to $18.00. They now have a "buy" rating on the stock.
Show more
Ratings data for OCUP provided by MarketBeat
Ocuphire Pharma, Inc. (NASDAQ: OCUP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Show more
Ratings data for OCUP provided by MarketBeat
Ocuphire Pharma, Inc. (NASDAQ: OCUP) had its price target lowered by analysts at Alliance Global Partners from $24.00 to $20.00. They now have a "buy" rating on the stock.
Show more
Ratings data for OCUP provided by MarketBeat
